Trials / NCT05841862
Intravitreal Quantum Dots (QD) for Advanced Retinitis Pigmentosa (RP) (QUANTUM)
Withdrawn N/A Drug / neuroprotection
Why it stopped: Lack of funding.
- Sponsor
- 2C Tech Corp
- Treatment
- 2C-QD; Sham 2C-QD
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa
- Ages
- 18 Years to no upper limit
- Enrollment
- Not stated participants
- Started
- 2024-03-20
- Main results expected
- 2025-03
- Results posted
- Not yet
- Record last updated
- 2025-06-12
What the study is testing
Pilot, randomized, observer and participant masked, sham and fellow eye controlled, interventional clinical device trail to evaluate the safety and effectiveness of the 2C-QD device to improve visual function in adults with advanced Retinitis Pigmentosa (RP).
Where it runs
No sites listed yet.